Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about LIPID: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| ASTROCYTE | accumulates_in | cell_type | 0.80 |
| Source | Relation | Type | Str |
|---|---|---|---|
| APOE | traffics | gene | 0.80 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| RBG treatment in ApoE-/- atherosclerosis mouse model | validation | atherosclerosis | 0.900 | 0.00 | ApoE-/- mice | proposed | N/A |
| Proposed experiment from debate on Senolytics targeting p16/p21+ senes | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Proposed experiment from debate on Microglia activate astrocytes via I | falsification | Neuroinflammation | 0.400 | 0.50 | cell_line | completed | $80,000 |
| Iron Dyshomeostasis in MSA Pathogenesis Experiment | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Biomechanical Impact Profiles and Chronic Traumatic Encephalopathy Phe | clinical | Neurodegeneration | 0.400 | 0.50 | in_silico | proposed | $180,000 |
| Ferroptosis Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Peroxisomal Dysfunction Validation in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Peroxisome Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Regulated Necrosis Validation Study in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Traumatic Brain Injury and Alzheimer's Disease Relationship | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Klebsiella pneumoniae Induces Ferroptosis and Lactation Dysfunction in Bovine Ma [PMID:40937759] | Mao P, Wang Z, Duan J, Dong P, Yuan C, L | J Agric Food Chem | 2025 | 1 |
| Targeting ferroptosis: novel therapeutic approaches and intervention strategies [PMID:41425591] | Luo Y, Long M, Wu X, Zeng L | Front Immunol | 2025 | 1 |
| Copy number deletion of PLA2G4A affects the susceptibility and clinical phenotyp [PMID:38816399] | Gao Z, Guo X, Sun Z, Wu S, Wang Q, Huang | Schizophrenia (Heidelb) | 2024 | 1 |
| Trimetazidine attenuates Ischemia/Reperfusion-Induced myocardial ferroptosis by [PMID:39134283] | Tan M, Yin Y, Chen W, Zhang J, Jin Y, Zh | Biochem Pharmacol | 2024 | 1 |
| The cell biology of APOE in the brain. [PMID:37805344] | Windham IA, Cohen S | Trends Cell Biol | 2024 | 1 |
| The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] | Maxine R Nelson, Peng Liu, Ayushi Agrawa | Nature neuroscience | 2023 | 1 |
| APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. [PMID:33658354] | Sienski G, Narayan P, Bonner JM, Kory N, | Sci Transl Med | 2021 | 1 |
| APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] | Serrano-Pozo A, Das S, Hyman BT | Lancet Neurol | 2021 | 1 |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] | Long JM, Holtzman DM | Cell | 2019 | 1 |
| Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] | Yamazaki Y, Zhao N, Caulfield TR, Liu CC | Nat Rev Neurol | 2019 | 1 |
| The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Mic [PMID:28930663] | Krasemann S, Madore C, Cialic R, Baufeld | Immunity | 2017 | 1 |
| Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: [PMID:21098459] | Mallat Z, Lambeau G, Tedgui A | Circulation | 2010 | 1 |
| Phospholipase A2 regulation of bovine endometrial (BEND) cell prostaglandin prod [PMID:18811942] | Godkin JD, Roberts MP, Elgayyar M, Guan | Reprod Biol Endocrinol | 2008 | 1 |
| Discovery of a glycosylated colchicine derivative as a neuroprotective agent for [PMID:41455281] | ["Jash M", "Gupta S", "Garg S", "Khan J" | European journal of medicinal | 2026 | 0 |
| The NADPH oxidase inhibitor Vas2870 prevents myocyte ferroptosis and improves ca [PMID:41671579] | Wang J, Li CM, Yang B, Tantai RN, Guo HX | British journal of pharmacolog | 2026 | 0 |
| Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] | Thedim M, Hu J, Maher M, Wiener-Kronish | Br J Anaesth | 2026 | 0 |
| Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] | Bae H, Song Z, Ali A, Sasaki T, Tesi N e | Geroscience | 2026 | 0 |
| Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] | Stern A, Linial M | Geroscience | 2026 | 0 |
| Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasi [PMID:40886963] | Zhu L, Du L, Wu J, Ding D, Wang J et al. | J Invest Dermatol | 2026 | 0 |
| Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsu [PMID:41101204] | Sang Y, Cao Y, Li S, Quan Y, Wang S et a | Biomaterials | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning LIPID in their description or question text
Score: 0.750 · neurodegeneration · 2026-04-25
Labile Fe2+ converts H2O2 into hydroxyl radicals, driving phospholipid peroxidation that consumes GSH and disables GPX4-
Score: 0.742 · neurodegeneration · 2026-04-02
## Mechanistic Overview APOE4-Selective Lipid Nanoemulsion Therapy starts from the claim that modulating APOE within the
Score: 0.732 · neurodegeneration · 2026-04-02
## Mechanistic Overview Senescence-Associated Myelin Lipid Remodeling starts from the claim that modulating PLA2G6/PLA2G
Score: 0.730 · neurodegeneration · 2026-04-02
## Mechanistic Overview Senescence-Induced Lipid Peroxidation Spreading starts from the claim that modulating GPX4/SLC7A
Score: 0.723 · neurodegeneration · 2026-04-02
## Mechanistic Overview Interfacial Lipid Mimetics to Disrupt Domain Interaction starts from the claim that modulating A
Score: 0.721 · neuroinflammation · 2026-04-22
## Mechanistic Overview Regional TREM2-Dependent Lipid Metabolism Determines Cortical Vulnerability in Alzheimer's Disea
Score: 0.710 · neurodegeneration · 2026-04-26
Motor neurons with ALS proteostasis stress may upregulate ACSL4/LPCAT3-dependent PUFA-phospholipid remodeling, creating
Score: 0.709 · neurodegeneration · 2026-04-02
## Mechanistic Overview Metabolic Circuit Breaker via Lipid Droplet Modulation starts from the claim that modulating PLI
Score: 0.697 · alzheimer · 2026-04-27
APOE ε4 promotes excessive cholesterol esterification and neutral lipid droplet accumulation in a discrete lipid-associa
Score: 0.694 · molecular-biology · 2026-04-24
A plausible upstream submechanism is that lipid-poor APOE4 disrupts ABCA1 trafficking, likely via ARF6-associated endoso
Score: 0.685 · neurodegeneration · 2026-04-25
Strongest mechanistic support among all hypotheses. TREM2-TYROBP signaling for DAM transition well-established. AL002 Ph
Score: 0.682 · neurodegeneration · 2026-04-04
## Molecular Mechanism and Rationale The apolipoprotein E4 (APOE4) allele represents the strongest genetic risk factor
Score: 0.681 · neuroscience · 2026-04-22
## **Molecular Mechanism and Rationale** The proposed mechanism centers on a catastrophic convergence of lipid homeosta
Score: 0.670 · neurodegeneration · 2026-04-25
Pharmacological FABP inhibition (BMS-309403) or siRNA targeting FABP5/7 interrupts intercellular lipid transfer between
Score: 0.668 · lipidomics · 2026-04-25
LXRβ-selective agonism represents a targeted strategy to simultaneously enhance APOE lipidation and reduce microglial ch